A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data

被引:11
作者
Ramos, Isaac Corro [1 ]
van voorn, George A. K. [2 ]
Vemer, Pepijn [3 ,4 ]
Feenstra, Talitha L. [3 ,5 ]
Al, Maiwenn J. [6 ]
机构
[1] Erasmus Univ, Inst Med Technol Assessment, Room J8-27,POB 1738, NL-3000 DR Rotterdam, Netherlands
[2] Wageningen Univ & Res, Biometris, Wageningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands
[4] Univ Groningen, Pharmacoepidemiol & Pharmacoecon PE2, Groningen, Netherlands
[5] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands
[6] Erasmus Univ, Inst Hlth Policy & Management, Rotterdam, Netherlands
关键词
decision making; health economics methods; statistics; validation; DECISION-ANALYTIC MODEL; CORE DIABETES MODEL; TASK-FORCE; VALIDATION; COMPLICATIONS; UNCERTAINTY; PREDICTION;
D O I
10.1016/j.jval.2017.04.016
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: The validation of health economic (HE) model outcomes against empirical data is of key importance. Although statistical testing seems applicable, guidelines for the validation of HE models lack guidance on statistical validation, and actual validation efforts often present subjective judgment of graphs and point estimates. Objectives: To discuss the applicability of existing validation techniques and to present a new method for quantifying the degrees of validity statistically, which is useful for decision makers. Methods: A new Bayesian method is proposed to determine how well HE model outcomes compare with empirical data. Validity is based on a preestablished accuracy interval in which the model outcomes should fall. The method uses the outcomes of a probabilistic sensitivity analysis and results in a posterior distribution around the probability that HE model outcomes can be regarded as valid. Results: We use a published diabetes model (Modelling Integrated Care for Diabetes based on Observational data) to validate the outcome "number of patients who are on dialysis or with end-stage renal disease." Results indicate that a high probability of a valid outcome is associated with relatively wide accuracy intervals. In particular, 25% deviation from the observed outcome implied approximately 60% expected validity. Conclusions: Current practice in HE model validation can be improved by using an alternative method based on assessing whether the model outcomes fit to empirical data at a predefined level of accuracy. This method has the advantage of assessing both model bias and parameter uncertainty and resulting in a quantitative measure of the degree of validity that penalizes models predicting the mean of an outcome correctly but with overly wide credible intervals.
引用
收藏
页码:1041 / 1047
页数:7
相关论文
共 41 条
[1]  
[Anonymous], 2012, BAYESIAN STAT INTRO
[2]   Handling uncertainty in cost-effectiveness models [J].
Briggs, AH .
PHARMACOECONOMICS, 2000, 17 (05) :479-500
[3]   Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6 [J].
Briggs, Andrew H. ;
Weinstein, Milton C. ;
Fenwick, Elisabeth A. L. ;
Karnon, Jonathan ;
Sculpher, Mark J. ;
Paltiel, A. David .
VALUE IN HEALTH, 2012, 15 (06) :835-842
[4]   Questionnaire to Assess Relevance and Credibility of Modeling Studies for Informing Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report [J].
Caro, J. Jaime ;
Eddy, David M. ;
Kan, Hong ;
Kaltz, Cheryl ;
Patel, Bimal ;
Eldessouki, Randa ;
Briggs, Andrew H. .
VALUE IN HEALTH, 2014, 17 (02) :174-182
[5]   Validation of an echo-Doppler decision model to predict left ventricular filling pressure in patients with heart failure independently of ejection fraction [J].
Dini, Frank Lloyd ;
Ballo, Piercarlo ;
Badano, Luigi ;
Barbier, Paolo ;
Chella, Piersilvio ;
Conti, Umberto ;
De Tommasi, Salvatore Mario ;
Galderisi, Maurizio ;
Ghio, Stefano ;
Magagnini, Enrico ;
Pieroni, Andrea ;
Rossi, Andrea ;
Rusconi, Cesare ;
Temporelli, Pier Luigi .
EUROPEAN JOURNAL OF ECHOCARDIOGRAPHY, 2010, 11 (08) :703-710
[6]   Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7 [J].
Eddy, David M. ;
Hollingworth, William ;
Caro, J. Jaime ;
Tsevat, Joel ;
McDonald, Kathryn M. ;
Wong, John B. ;
Force, ISPOR-SMDM Modeling Good Res Practices Task .
MEDICAL DECISION MAKING, 2012, 32 (05) :733-743
[7]  
EDDY DM, 1987, CANCER-AM CANCER SOC, V60, P1117, DOI 10.1002/1097-0142(19870901)60:5<1117::AID-CNCR2820600533>3.0.CO
[8]  
2-H
[9]   Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making [J].
Franken, Margreet ;
Nilsson, Fredrik ;
Sandmann, Frank ;
de Boer, Anthonius ;
Koopmanschap, Marc .
PHARMACOECONOMICS, 2013, 31 (09) :781-797
[10]   Empirically Evaluating Decision-Analytic Models [J].
Goldhaber-Fiebert, Jeremy D. ;
Stout, Natasha K. ;
Goldie, Sue J. .
VALUE IN HEALTH, 2010, 13 (05) :667-674